ErbB-2 selective small molecule kinase inhibitors
    74.
    发明授权
    ErbB-2 selective small molecule kinase inhibitors 失效
    ErbB-2选择性小分子激酶抑制剂

    公开(公告)号:US07427689B2

    公开(公告)日:2008-09-23

    申请号:US10343267

    申请日:2001-07-30

    CPC classification number: A61K31/216 A61K31/00 A61K31/192

    Abstract: A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(p-nitrophenyl)-2-propynoate.

    Abstract translation: 化合物的erbB-2激酶抑制的新方法通过计算建模和数据处理鉴定,和/或合理和从头药物设计提供了化合物结合erbB-2激酶分子,并且其可以用作erbB-2激酶激动剂或拮抗剂 。 这些化合物特别用于治疗癌症,特别是乳腺癌,并且可以单独使用或与其它化学治疗剂,特别是与赫氏原,人源化抗HER-2抗体或放射治疗组合使用。 例示的具体化合物是“化合物B17”=甲基 - (对硝基苯基)-2-丙炔酸酯。

Patent Agency Ranking